# Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

> **NCT00773734** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 352 (actual)

## Conditions studied

- Psoriasis
- Plaque-type Psoriasis

## Interventions

- **DRUG:** Apremilast 10mg
- **DRUG:** Apremilast 20mg
- **DRUG:** Apremilast 30 mg
- **DRUG:** Placebo
- **DRUG:** Apremilast 30mg
- **DRUG:** Apremilast 20mg

## Key facts

- **NCT ID:** NCT00773734
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-01
- **Primary completion:** 2009-08-01
- **Final completion:** 2015-05-20
- **Target enrollment:** 352 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00773734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00773734, "Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00773734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*